Citation Impact
Citing Papers
Alpha- versus Beta-Particle Radiopeptide Therapy in a Human Prostate Cancer Model (213Bi-DOTA-PESIN and 213Bi-AMBA versus177Lu-DOTA-PESIN)
2011
Correlation of Red Marrow Radiation Dosimetry with Myelotoxicity: Empirical Factors Influencing the Radiation-Induced Myelotoxicity of Radiolabeled Antibodies, Fragments and Peptides in Pre-Clinical and Clinical Settings
2002
Intracellular Delivery System for Antibody–Peptide Drug Conjugates
2015 StandoutNobel
Radioimmunotherapy of Breast Cancer Metastases with α-Particle Emitter 225Ac: Comparing Efficacy with 213Bi and 90Y
2009
MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by 213Bi-C595 radioimmunoconjugate
2004
Alpha-Particle Emitting Atomic Generator (Actinium-225)-Labeled Trastuzumab (Herceptin) Targeting of Breast Cancer Spheroids
2004
Molecular imaging in drug development
2008 Standout
Evolutionary dynamics of carcinogenesis and why targeted therapy does not work
2012
Applications of novel drug delivery system for herbal formulations
2010 Standout
Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective
2009 Standout
Antibody therapy for residual disease in acute myelogenous leukemia
2001
Antibody-targeted radiation cancer therapy
2004
Advancements in cancer therapy with alpha-emitters: a review
2001
In vitro and in vivo evaluation of novel ligands for radioimmunotherapy
2006
The past and future of CD33 as therapeutic target in acute myeloid leukemia
2014
Cancer Statistics, 2006
2006 Standout
Cancer stem cells revisited
2017 Standout
Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging?
2011
Design and synthesis of 225Ac radioimmunopharmaceuticals
2002
Liposome: classification, preparation, and applications
2013 Standout
To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery
2010 Standout
Towards translation of 212Pb as a clinical therapeutic; getting the lead in!
2011
Polymer conjugates as anticancer nanomedicines
2006 Standout
Preclinical evaluation of NETA-based bifunctional ligand for radioimmunotherapy applications using 212Bi and 213Bi: Radiolabeling, serum stability, and biodistribution and tumor uptake studies
2013
In Vivo Evaluation of Bismuth-Labeled Monoclonal Antibody Comparing DTPA-Derived Bifunctional Chelates
2001
Measuring the multifaceted roles of mucin-domain glycoproteins in cancer
2022 StandoutNobel
Radioimmunotherapy of human tumours
2015
Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view
2007
Liposomes as targeted drug delivery systems in the treatment of breast cancer
2006
Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody
2011
HER1-Targeted 86Y-Panitumumab Possesses Superior Targeting Characteristics than 86Y-Cetuximab for PET Imaging of Human Malignant Mesothelioma Tumors Xenografts
2011
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
2021 StandoutNobel
Strategies in the design of nanoparticles for therapeutic applications
2010 Standout
Matching chelators to radiometals for radiopharmaceuticals
2013 Standout
Antimony and bismuth compounds in oncology
2002
Development of therapeutic antibodies for the treatment of diseases
2020 Standout
Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial
2010
Immunogenic cell death and DAMPs in cancer therapy
2012 Standout
Cancer Therapy with Radiolabeled and Drug/Toxin-conjugated Antibodies
2005
Evaluation of a Maleimido Derivative of CHX-A′′ DTPA for Site-Specific Labeling of Affibody Molecules
2008
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
New Strategies for Fluorescent Probe Design in Medical Diagnostic Imaging
2009 Standout
Design, Synthesis, and Characterization of a Dual Modality Positron Emission Tomography and Fluorescence Imaging Agent for Monoclonal Antibody Tumor-Targeted Imaging
2007
Relationship between Size and Function of Natural Substance Particles
2011
Efficient Bifunctional Decadentate Ligand 3p-C-DEPA for Targeted α-Radioimmunotherapy Applications
2011
Unconventional nuclides for radiopharmaceuticals.
2010
Investigational CD33-targeted therapeutics for acute myeloid leukemia
2018
The Development of the α-Particle Emitting Radionuclides 212Bi and 213Bi, and Their Decay Chain Related Radionuclides, for Therapeutic Applications
2001
Uncommon heavy metals, metalloids and their plant toxicity: a review
2008 Standout
Unconventional Nuclides for Radiopharmaceuticals
2010
Potent Antitumor Activity of an Auristatin-Conjugated, Fully Human Monoclonal Antibody to Prostate-Specific Membrane Antigen
2006
213Bi-[DOTA0, Tyr3]Octreotide Peptide Receptor Radionuclide Therapy of Pancreatic Tumors in a Preclinical Animal Model
2006
Impact of Natural Products on Developing New Anti-Cancer Agents
2009 Standout
Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.
2003
Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates.
2004
Bifunctional chelates for metal nuclides.
2008
Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI.
2003
Evaluation of CD20, CD22, and HLA-DR Targeting for Radioimmunotherapy of B-Cell Lymphomas
2007
H2azapa: a Versatile Acyclic Multifunctional Chelator for 67Ga, 64Cu, 111In, and 177Lu
2012
The return of metabolism: biochemistry and physiology of the pentose phosphate pathway
2014 Standout
Risk assessment in haematopoietic stem cell transplantation: Conditioning
2007
Radiometals for Combined Imaging and Therapy
2012
The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development
2005
Works of R. Molinet being referenced
Cyclotron production of Ac-225 for targeted alpha therapy11Dedicated to Prof. Dr. Franz Baumgärtner on the occasion of his 75th birthday.
2004
Cytotoxicity of 213Bi- and 225Ac-immunoconjugates
1995
In vitro evaluation of 213Bi-rituximab versus external gamma irradiation for the treatment of B-CLL patients: relative biological efficacy with respect to apoptosis induction and chromosomal damage
2003
Production of Ac-225 from Th-229 for Targeted α Therapy
2005
Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry.
1999
Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters.
1999
Validation of 213Bi-alpha radioimmunotherapy for multiple myeloma.
1999
High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
1999
Targeted α particle immunotherapy for myeloid leukemia
2002